Update: Sales growth with Allersys menu development
Development of the automated Allersys allergy test menu is progressing well, with 36 optimised assays, up from 32 in July, and with 40 targeted for launch. Omega’s Visitect CD4 test to monitor HIV patients is still resolving a stability issue with good progress being made but no timeline yet visible. H116 trading showed a 20% food intolerance gain but the German allergy market remains weak with a 13% fall. Infectious disease gained sales from a low base. Management expects adjusted EBIT will be level with H115 at c £0.56m after an 8% actual sales gain.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.